Evidence map›Paper›PMID 42511891›Full record

ArticleBiomedicines2026

Real-World Dupilumab in Type 2 Chronic Obstructive Pulmonary Disease (COPD): A Single-Centre Compassionate-Use Case Series.

Pier-Valerio Mari, Lorenzo Carriera, Alberto Ricci, Angelo Coppola, Simone Ielo, Alessandro D'Occhio, Armando Edoardo Ibello, Veronica Ojetti

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07788092 (Real-World Lung Function and Symptom Response to Dupilumab in Type 2-Inflamed Chronic Obstructive Pulmonary Disease Across the Full Spectrum of Airflow Limitation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07788092 completednot on this map

Real-World Lung Function and Symptom Response to Dupilumab in Type 2-Inflamed Chronic Obstructive Pulmonary Disease Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study

TypeobservationalSponsorAzienda Ospedaliera di PerugiaRan2024 to 2026Enrolled40ConditionsCOPD (Chronic Obstructive Pulmonary Disease), COPD, EosinophiliaArmsDupilumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pier-Valerio MariInternal Medicine, San Carlo di Nancy Hospital, Via Aurelia 275, 00165 Rome, Italy.ORCID 0000-0002-3307-217X
Lorenzo CarrieraFaculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0009-0006-2538-1278
Alberto RicciDivision of Pneumology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU Sant'Andrea, 00189 Rome, Italy.ORCID 0000-0002-1718-1587
Angelo CoppolaUOC Pneumologia, Ospedale San Filippo Neri-ASL Roma 1, 00135 Rome, Italy.ORCID 0000-0002-0819-5936
Simone IeloUOC Pneumologia e UTIP, Ospedale San Donato, USL Toscana SudEst, 52100 Arezzo, Italy.ORCID 0009-0002-2838-423X
Alessandro D'OcchioFaculty of Medicine, UniCamillus International Medical University of Rome, 00131 Rome, Italy.
Armando Edoardo IbelloFaculty of Medicine, UniCamillus International Medical University of Rome, 00131 Rome, Italy.
Veronica OjettiInternal Medicine, San Carlo di Nancy Hospital, Via Aurelia 275, 00165 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CATchronic bronchitisCOPDdupilumabeosinophilsmucus hypersecretionprecision medicinetreatable traitstype 2 inflammation

Identifiers

PMID42511891
PMCPMC13404109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.